RT Journal Article
SR Electronic
T1 Robustness of a Restriction Spectrum Imaging (RSI) quantitative MRI biomarker for prostate cancer: assessing for systematic bias due to age, race, ethnicity, prostate volume, medication use, or imaging acquisition parameters
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.10.24313042
DO 10.1101/2024.09.10.24313042
A1 Do, Deondre D
A1 Domingo, Mariluz Rojo
A1 Conlin, Christopher C
A1 Matthews, Ian
A1 Kallis, Karoline
A1 Baxter, Madison T
A1 Ollison, Courtney
A1 Song, Yuze
A1 Xu, George
A1 Zhong, Allison Y
A1 Bagrodia, Aditya
A1 Barrett, Tristan
A1 Cooperberg, Matthew
A1 Feng, Felix
A1 Hahn, Michael E
A1 Harisinghani, Mukesh
A1 Hollenberg, Gary
A1 Javier-Desloges, Juan
A1 Kamran, Sophia C.
A1 Kane, Christopher J
A1 Kessler, Dimitri
A1 Kuperman, Joshua
A1 Lee, Kang-Lung
A1 Levine, Jonathan
A1 Liss, Michael A
A1 Margolis, Daniel JA
A1 Murphy, Paul M
A1 Nakrour, Nabih
A1 Ohliger, Michael A.
A1 Osinski, Thomas
A1 Pamatmat, Anthony James
A1 Pompa, Isabella R
A1 Rakow-Penner, Rebecca
A1 Roberts, Jacob L
A1 Santhosh, Karan
A1 Shabaik, Ahmed S
A1 Song, David
A1 Tempany, Clare M
A1 Trecarten, Shaun
A1 Wehrli, Natasha
A1 Weinberg, Eric P
A1 Woolen, Sean
A1 Dale, Anders M
A1 Seibert, Tyler M
YR 2024
UL http://medrxiv.org/content/early/2024/09/12/2024.09.10.24313042.abstract
AB Introduction Prostate multiparametric magnetic resonance imaging (mpMRI) has greatly improved the detection of clinically significant prostate cancer (csPCa). However, the limited number of expert sub-specialist radiologists capable of interpreting conventional prostate mpMRI is a bottleneck for universal access to this healthcare advance. A reliable and reproducible quantitative imaging biomarker could facilitate implementation of accurate prostate MRI at clinical sites with limited experience, thus ensuring more equitable patient care. Restriction Spectrum Imaging restriction score (RSIrs) is an MRI biomarker that has shown the ability to enhance the qualitative and quantitative interpretation of prostate MRI. However, patient-level factors (age, race, ethnicity, prostate volume, and 5-alpha-reductase inhibitor (5-ARI) use) and acquisition-level factors (scanner manufacturer/model and protocol parameters) can affect prostate mpMRI, and their impact on quantitative RSIrs is unknown.Methods RSI data from patients with known or suspected csPCa were collected from seven centers. We estimated effects of patient and acquisition factors on prostate voxels overall (Method 1: benign patients only) and on only the maximum RSIrs within each prostate (RSIrsmax; Method 2: benign and csPCa patients) using linear models. We then tested whether adjusting for any estimated systematic biases would improve performance of RSIrs for patient-level detection of csPCa, as measured by area under the ROC curve (AUC).Results Using both Method 1 and Method 2, we observed statistically significant effects on RSIrs of age and acquisition group (p < 0.05). Prostate volume had significant effects using only Method 2. All of these effects were small, and adjusting for them did not improve csPCa detection performance (p ≥ 0.05). AUC of RSIrsmax for patient-level csPCa detection was 0.77 (95% CI: 0.75, 0.79) unadjusted, compared to 0.77 (0.76, 0.79) and 0.74 (0.72, 0.76) after adjustment using Method 1 and 2 respectively.Conclusion Age, prostate volume, and imaging acquisition factors may lead to systematic differences in RSIrs, but these effects are small and have minimal impact on performance of RSIrs for detection of csPCa. RSIrs can be used as a reliable biomarker across a wide range of patients, centers, scanners, and acquisition factors.Competing Interest StatementTyler M. Seibert. reports honoraria from CorTechs Labs, Varian Medical Systems, WebMD, GE Healthcare, and Janssen; has an equity interest in CorTechs Labs, Inc, and serves on its scientific advisory board; and has received in-kind research support from GE Healthcare via a research agreement with the University of California, San Diego. These companies might potentially benefit from the research results. The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict-of-interest policies. Michael E. Hahn reports honoraria from Multimodal Imaging Services Corporation and research funding from GE Healthcare. Anders M. Dale. is a founder of and holds equity in CorTechs Labs, Inc, and serves on its scientific advisory board; he also is a member of the scientific advisory board of Human Longevity, Inc, and receives funding through research agreements with GE Healthcare. Rebecca Rakow-Penner Human Longevity Inc: Consultant Cortech Labs: Stock options Curemetrix: Stock options, consultant Imagine Scientific, advisory board. SBIR GE Healthcare, research agreement Bayer consultant Michael Liss Founder/President of Oncobiomix with no relation to this manuscript. Sean Woolen Research grants paid to institution from Siemens Healthineers and General Electric. Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R01CA279667. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Funding StatementThis work was supported, in part, by the National Institutes of Health (NIH/NIBIB K08EB026503, NIH UL1TR000100), the American Society for Radiation Oncology, the Prostate Cancer Foundation (PCF20YOUN01), and the U.S. Department of Defense (DOD/CDMRP PC220278).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of University of California, San Diego gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors